US$ 24.51
off-label use of glp-1 agonists for obesity in 2016 Weight Reduction with and Paths Discontinuation While Maintaining Weight Loss What Are GLP-1 Agonists For
Description
[32], who also combined RCTs with non-RCTs

The prevalence of complications associated with obesity, including dyslipidaemia, hypertension, fatty liver disease and psychosocial complications are becoming increasingly prevalent within the paediatric populations

Hua Medicine Ltd

GLP-1RA: standardized mean difference -0.27

Nauck et al., 2021a)
